PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29992039-3 2018 Losartan potassium (losartan) is an angiotensin II receptor blocker (ARB) that reduces PAI-1 production and improves insulin sensitivity that has been proposed as a treatment for pediatric NAFLD but has not previously been tested. Losartan 0-18 serpin family E member 1 Homo sapiens 87-92 29992039-3 2018 Losartan potassium (losartan) is an angiotensin II receptor blocker (ARB) that reduces PAI-1 production and improves insulin sensitivity that has been proposed as a treatment for pediatric NAFLD but has not previously been tested. Losartan 20-28 serpin family E member 1 Homo sapiens 87-92 17175314-1 2006 We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients. Losartan 29-37 serpin family E member 1 Homo sapiens 99-132 27064499-6 2016 Six-month treatment with ramipril or losartan resulted in a similar effect upon PAI-1, NT-proBNP, EF, and CT levels in survivors of STEMI, but in comparison to control group, receiving DAPT alone, ramipril or losartan treatment with DAPT significantly increased mean CT (226.7 +- 80.3 sec versus 158.1 +- 80.3 sec, p < 0.05). Losartan 37-45 serpin family E member 1 Homo sapiens 80-85 19589241-5 2009 Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Losartan 0-8 serpin family E member 1 Homo sapiens 38-43 19589241-5 2009 Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Losartan 0-8 serpin family E member 1 Homo sapiens 56-61 17175314-1 2006 We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients. Losartan 29-37 serpin family E member 1 Homo sapiens 134-139 17175314-1 2006 We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients. Losartan 39-42 serpin family E member 1 Homo sapiens 99-132 17175314-1 2006 We previously confirmed that losartan (LOS), an angiotensin-II (A-II) receptor blocker, diminished plasminogen activator inhibitor-1 (PAI-1) in cyclosporine (CsA)-treated renal graft recipients. Losartan 39-42 serpin family E member 1 Homo sapiens 134-139 17536885-3 2003 The objective of this study was to evaluate, in patients with mild to moderate hypertension, the change in tissue plasminogen activator (t-PA) and PAI-1 plasma levels after treatment with an AT(1)-receptor blocker (losartan 50 mg/day) or an ACE inhibitor (delapril 60 mg/day). Losartan 215-223 serpin family E member 1 Homo sapiens 147-152 14659871-0 2003 Different effects of losartan and delapril on plasma PAI-1 levels in patients with mild to moderate hypertension. Losartan 21-29 serpin family E member 1 Homo sapiens 53-58 15194475-5 2004 PAI-1 expression and protein secretion induced by Ang II in 4G/4G HUVEC was completely inhibited by preincubation with 0.05 microM losartan (p<0.01), indicating an AT1-mediated effect. Losartan 131-139 serpin family E member 1 Homo sapiens 0-5 15194475-7 2004 CONCLUSIONS: The 4G/5G PAI-1 polymorphism determines the endothelial PAI-1 upregulation by Ang II and the inhibitory response to losartan. Losartan 129-137 serpin family E member 1 Homo sapiens 23-28 17536885-14 2003 The losartan group demonstrated significantly higher post-treatment PAI-1 values than the delapril group (p = 0.048). Losartan 4-12 serpin family E member 1 Homo sapiens 68-73 11602818-6 2001 Losartan alone increased secretion of tPA, MMP-2 activity, and TIMPs and decreased secretion of PAI-1. Losartan 0-8 serpin family E member 1 Homo sapiens 96-101 12468570-8 2002 Addition of either ramipril or losartan significantly decreased plasma PAI-1 antigen (P=0.046). Losartan 31-39 serpin family E member 1 Homo sapiens 71-76 12468570-9 2002 However, the effect of losartan on PAI-1 antigen was not sustained throughout the 6-week treatment period, such that there was a significant drugxtime interaction (P=0.043). Losartan 23-31 serpin family E member 1 Homo sapiens 35-40 11991216-0 2002 Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Losartan 0-8 serpin family E member 1 Homo sapiens 43-76 11991216-1 2002 BACKGROUND: This study compared the effects of losartan and perindopril on plasma plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in hypertensive type 2 diabetic patients. Losartan 47-55 serpin family E member 1 Homo sapiens 82-115 11991216-1 2002 BACKGROUND: This study compared the effects of losartan and perindopril on plasma plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in hypertensive type 2 diabetic patients. Losartan 47-55 serpin family E member 1 Homo sapiens 117-122 10604482-9 1999 Increased plasma levels of PAI-1 antigen, PAI-1 activity, and sTM were reduced in patients after they were given perindopril and losartan (P<.005); the reductions in losartan-receiving group were more pronounced (P<.05). Losartan 129-137 serpin family E member 1 Homo sapiens 27-32 11587159-1 2001 The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women. Losartan 69-77 serpin family E member 1 Homo sapiens 81-119 10821336-9 2000 In spite of the marked further rise in PRA after losartan, the stimulation of PAI-1 antigen and activity was blunted by losartan (24.4 +/- 3.6 ng/mL and 4.55 +/- 0.99 IU/mL, respectively). Losartan 120-128 serpin family E member 1 Homo sapiens 78-83 10604482-9 1999 Increased plasma levels of PAI-1 antigen, PAI-1 activity, and sTM were reduced in patients after they were given perindopril and losartan (P<.005); the reductions in losartan-receiving group were more pronounced (P<.05). Losartan 129-137 serpin family E member 1 Homo sapiens 42-47 10604482-9 1999 Increased plasma levels of PAI-1 antigen, PAI-1 activity, and sTM were reduced in patients after they were given perindopril and losartan (P<.005); the reductions in losartan-receiving group were more pronounced (P<.05). Losartan 169-177 serpin family E member 1 Homo sapiens 27-32 10604482-9 1999 Increased plasma levels of PAI-1 antigen, PAI-1 activity, and sTM were reduced in patients after they were given perindopril and losartan (P<.005); the reductions in losartan-receiving group were more pronounced (P<.05). Losartan 169-177 serpin family E member 1 Homo sapiens 42-47 10454455-10 1999 PAI-1 activity was lower during treatment with quinapril than with losartan (P=0.015). Losartan 67-75 serpin family E member 1 Homo sapiens 0-5 10368114-5 1999 Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1 (38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in PAI-1 (48%; P=0.01) activity. Losartan 24-32 serpin family E member 1 Homo sapiens 93-98 10368114-5 1999 Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1 (38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in PAI-1 (48%; P=0.01) activity. Losartan 24-32 serpin family E member 1 Homo sapiens 216-221 10368114-6 1999 Changes in plasma fibrinolytic parameters were more marked during losartan treatment (P<0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (P<0.05). Losartan 66-74 serpin family E member 1 Homo sapiens 140-145 30712667-7 2019 At 1% oxygen, losartan significantly reduced intracellular VEGFA and SERPINE1 levels and secreted VEGF levels (P = 0.008, 0.0001 and 0.0001). Losartan 14-22 serpin family E member 1 Homo sapiens 69-77